Home / Market News / $CLMB
fiscal.ai Corporate Catalyst Impact 75/100 ● negative

Climb Bio and Mabworks Announce CLYM116/MIL116 Data at ASN Kidney Week 2026

Oct 23, 2026, 9:34 PM UTC · Primary ticker $CLMB

Climb Bio and Mabworks announced positive clinical data for their therapeutic candidate CLYM116/MIL116, demonstrating strong efficacy in suppressing free APRIL and reducing Gd-IgA1, supporting a favorable dosing schedule. This data is a significant positive development for the companies, validating the drug's potential and de-risking its ongoing Phase 2 trial.

Climb Bio and Mabworks released new data for CLYM116/MIL116 at ASN Kidney Week 2026, showing over 90% free APRIL suppression sustained for 12 weeks and a 70% reduction in Gd-IgA1. This is significant because it supports a convenient quarterly dosing interval (Q12W) and demonstrates strong therapeutic efficacy, which are critical factors for drug adoption and market potential. This positive data de-risks the ongoing NAVIGATE-2 Phase 2 trial and could lead to increased investor confidence in the short term for both Climb Bio and Mabworks. The long-term implication is a higher probability of successful clinical development and eventual market approval, representing a key opportunity for traders looking for biotech catalysts.

$CLMB positive Positive clinical trial data for key therapeutic candidate
$MABW positive Positive clinical trial data for co-developed therapeutic candidate
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.